近25亿元股票分给两个女儿！知名企业董事长拟彻底退隐

Core Viewpoint - The recent equity transfer involving Zhongbei Group and Taizhou Gede marks a significant restructuring within the company, with the founder's family members taking over control, while the founder, Hua Xuande, steps back due to age considerations [4][6][16]. Group 1: Equity Transfer Details - Hua Lirong acquired 28.50% of Zhongbei Group's shares for 41.33 million yuan, while Hua Xiaohui acquired 14% for 20.48 million yuan [1]. - Following the transfer, Hua Lirong will hold 51.00% of Zhongbei Group and 5.00% of Taizhou Gede, while Hua Xiaohui will hold 36.50% of Zhongbei Group and 5.00% of Taizhou Gede [4]. Group 2: Company Performance and Background - As of November 11, Zhongbei Group and Taizhou Gede hold shares in Jiuzhou Pharmaceutical valued at approximately 5.636 billion yuan and 807 million yuan, respectively, based on Jiuzhou's closing price of 19.88 yuan per share [6]. - Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for Q3 2025, ranking 5th in its industry, surpassing the industry average of 2.547 billion yuan [7][16]. - The company has evolved from a small flavoring factory to a leading player in the pharmaceutical industry, with significant growth attributed to strategic decisions made by Hua Xuande [9][13]. Group 3: Leadership Transition - Hua Xuande, born in 1943 and currently 82 years old, has been a pivotal figure in the development of Zhongbei Group and Jiuzhou Pharmaceutical, but has recently stepped back from active management [6][9]. - The leadership has transitioned to his daughter, Hua Lirong, who now serves as the chairman of Jiuzhou Pharmaceutical, indicating a shift in management dynamics within the company [16][18].